GSK’s RSVPreF3 OA vaccine (AREXVY) : AREXVY was approved by FDA on May 3, 2023, and is indicated for the prevention of LRTD disease caused by RSV in adults 60 and older, as a single dose
CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i

GSK’s RSVPreF3 OA vaccine (AREXVY) : AREXVY was approved by FDA on May 3, 2023, and is indicated for the prevention of LRTD disease caused by RSV in adults 60 and older, as a single dose

Filetype[PDF-1.21 MB]


English

Supporting Files

  • No Additional Files
More +

Related Documents

You May Also Like

Checkout today's featured content at stacks.cdc.gov